A Better Mistake Custom Case Solution & Analysis

Evidence Brief: Business Case Data Research

1. Financial Metrics

• Annual Revenue: 450 million dollars for the core product line.
• Market Share: 38 percent in the surgical device segment.
• Recall Cost Estimate: 120 million to 180 million dollars including logistics and legal reserves.
• Operating Margin: 14 percent, currently declining due to increased R and D spending.
• Stock Price Volatility: 12 percent higher than industry average over the last quarter.

2. Operational Facts

• Product: Gamma-9 surgical stent.
• Defect Nature: Testing data from 2021 contains a calculation error regarding tensile strength.
• Current Status: The product meets safety standards in practice, but the filing data is technically fraudulent.
• Volume: 85,000 units currently implanted or in hospital inventory.
• Manufacturing: Single-site production in Ohio.

3. Stakeholder Positions

• Sarah (VP Operations): Discovered the error; advocates for immediate disclosure to maintain personal and corporate integrity.
• Marcus (CEO): Concerned with short-term stock price and potential bankruptcy; prefers internal remediation without public filing.
• General Counsel: Advises that the legal risk of disclosure is high, but the criminal risk of concealment is higher.
• Board of Directors: Currently unaware of the specific data discrepancy.

4. Information Gaps

• Actual failure rate of the Gamma-9 in long-term longitudinal studies (beyond 3 years).
• Specific stance of the lead FDA auditor assigned to the upcoming biennial review.
• Competitor readiness to fill the market gap if a recall is initiated.

Strategic Analysis: Market Strategy Consultant

1. Core Strategic Question

• How can the firm rectify a historical regulatory non-compliance without triggering an existential financial crisis?
• Can the organization survive the reputational damage of a voluntary recall versus the legal catastrophe of a forced one?

2. Structural Analysis

The competitive environment is defined by high switching costs and heavy regulation. Porter’s Five Forces reveals that buyer power is concentrated in large hospital networks that prioritize reliability over price. A data integrity failure undermines the primary value proposition. The Value Chain analysis indicates that the firm’s competitive advantage rests entirely on its R and D and regulatory approval pipeline. If the relationship with the regulator is severed, the pipeline dies.

3. Strategic Options

Option A: Full Voluntary Disclosure and Recall. Immediate notification to the regulator and a complete market withdrawal of affected lots. This preserves long-term credibility but risks immediate insolvency and shareholder lawsuits.

Option B: Proactive Regulatory Correction. Disclose the data error to the regulator as a self-identified administrative lapse. Argue that the product remains safe based on real-world evidence. This seeks to avoid a recall while fixing the legal record.

Option C: Internal Remediation. Fix the testing protocols for all future batches and bury the historical error. This avoids financial loss now but creates a permanent risk of criminal prosecution if discovered.

4. Preliminary Recommendation

Pursue Option B. The firm must prioritize its relationship with the regulator. Real-world clinical data suggests the product is safe despite the flawed filing. By framing this as a voluntary data correction rather than a safety defect, the firm can negotiate a phased update rather than a catastrophic recall.

Implementation Roadmap: Operations and Implementation Planner

1. Critical Path

• Week 1: Conduct an exhaustive internal audit to verify that no actual patient harm has occurred.
• Week 2: Prepare a technical briefing for the regulator demonstrating that current product performance exceeds the faulty 2021 specifications.
• Week 3: Secure a bridge credit facility to ensure liquidity if the market reacts poorly to the announcement.
• Week 4: Execute a controlled disclosure to the regulator and key hospital partners simultaneously.

2. Key Constraints

• Regulatory Discretion: The agency may reject the administrative correction and mandate a recall regardless of current safety data.
• Liquidity: The firm has less than 60 days of cash on hand if hospital payments are frozen during the review period.

3. Risk-Adjusted Implementation Strategy

The plan assumes the regulator will value transparency. To mitigate the risk of a forced recall, the firm will prepare a 90-day inventory of the Gamma-10 (the updated model) to replace Gamma-9 units if necessary. Contingency planning includes a pre-packaged reorganization plan if legal liabilities exceed 200 million dollars.

Executive Review and BLUF

1. BLUF

The company must disclose the data error to the regulator within 10 business days. Silence is not a viable strategy; the error will be found during the next audit, turning a civil matter into a criminal one. The strategy focuses on proactive disclosure to avoid a full product recall. By proving the product is safe in practice, we can transition the conversation from a safety crisis to a documentation correction. This path preserves the company’s license to operate while managing the financial downside.

2. Dangerous Assumption

The analysis assumes the regulator will differentiate between fraudulent data and a dangerous product. In a high-stakes medical environment, regulators often treat data integrity breaches with the same severity as product failures to deter future misconduct.

3. Unaddressed Risks

4. Unconsidered Alternative

The team did not evaluate a strategic sale of the business unit to a larger competitor with a deeper balance sheet. A larger firm could absorb the legal costs and regulatory fallout more effectively than a standalone entity, potentially preserving some shareholder value through an asset sale before the news becomes public.

5. MECE Verdict

APPROVED FOR LEADERSHIP REVIEW. The recommendations are mutually exclusive and collectively exhaustive regarding the immediate operational and ethical choices available to the board.